Melola Discovery

← Melola Discovery

Journal SINTA 1

Review Article and Clinical Experience: Pleiotropic Properties of Statins (Potential Benefits of “PECA-GOMES” for the Elderly)

Folia Medica Indonesiana · Vol. 39 No. 2 (2003)

ISSN
2355-8393, 2599-056X
Published
2003-04-01
Publisher
Airlangga University
Language
en

Abstract

Five major risk factors that modify LDL-Goals are (ATP-III 2001): family history of premature CHD, age (men ≥ 45 years; women ≥ 55 years), hypertension (BP ≥ 140/90 mmHg or on antihypertensive medication), low-HDL-Chol (<40 mg/dl), and cigarette. Thus, it is obvious that the elderly can be included in one risk factor. In ATP-IIII, Diabetes Mellitus (DM) is regarded as a CHD risk equivalent. HDL-Chol ≥ 60 mg/dl counts as a “protective” factor; its presence removes one risk factor from the total count. Coronary Heart Disease (esp. for the elderly) remains a major therapeutic challenge in the world, and strategies aimed at cholesterol lowering from the primary target of treatment (LDL-Cholesterol < 100 mg/dl) for patients with CHD, DM, and “Double Jeopardy” (DM plus CHD). Decreased LDL size is mainly associated with premature CHD, but it is likely that LDL particle size is not a major risk factor in the elderly. Three categories of risk that modify LDL Chol (mg/dl). Goals are:CHD and CHD risk equivalent (LDL <100), Multiple (2+) risk factors (LDL <130), Zero to one risk factor (LDL <160). Statins (1 st Gen: Lovastatin, Simvastatin, Pravastatin; 2 nd Gen: Fluvastatin; 3 rd Gen: Atorvastatin, Resuvastatin) have the primary effect to reduce LDL-Chol. However, emerging evidence indicate that Statins (f.e Atorvastatin in MIRACL, AVERT, ASAP-Clinical Trials) reduce the incidence of recurrent ischemic events, and slow the progression of atherosclerotic CHD. These clinical effects may be due to the pleiotropic effects (non-lipid mechanism) of Statins. Many of the pleiotropic properties (minimally 20 items) of the Statins have been compiled by the author, and 9 of 20 such beneficial effects can be abbreviated as PECA-GOMES (stimulate Plaque Stabilization, improve Endothelial and Platelet Function, Cellular Immunity, Anti inflammatory Response – No Glucose Intolerance Effect, lower Oxidied LDL, decrease Macrophage number, inhibit Endothelin production, suppress SMC Proliferation and Migration). It is most likely that these non-lipid properties may play pivotal roles in plaque stabilization and in improving endothelial and platelet function which then contribute to an antithrombotic effect. Conclusion: Taken together, the results of several studies indicate that the effects of Statins may extend beyond cholesterol lowering. PECA-GOMES effects of Statins may be of great therapeutical benefits for the elderly. The results of Atorvastatin Trials support the pleiotropic effect of Statins in clinical practice.

Keywords

Collaboration network of the authors

8 authors · 16 co-authorship links · 7 across different organisations

Hover or tap a name to highlight its co-authors. Double-click to open the author's page.

  • Universitas Airlangga
  • University of Brawijaya
  • Rumah Sakit Umum Pusat Dr. Sardjito
  • Affiliation unknown
  • Different organisations
  • Same organisation
  • Affiliation unknown
  • Thicker line = more joint articles · bigger circle = more articles
Show as table
Co-authorOrganisationJoint articles
Agung Sindu PranotoUniversitas Airlangga1
Hermina NovidaUniversitas Airlangga1
Jongky Hendro PrayitnoAffiliation unknown1
Adeodatus Yuda HandayaRumah Sakit Umum Pusat Dr. Sardjito1
Djanggan SargowoUniversity of Brawijaya1
Diana LyrawatiUniversity of Brawijaya1
Mohammad Aris WidodoUniversity of Brawijaya1

Affiliations come from OpenAlex; journal OAI-PMH metadata carries none. Authors without an OpenAlex ID are matched by name, which can merge or split people.

Metadata source: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S4210179714, first harvested 19 Nov 2026, last seen 19 Nov 2026.
Original metadata (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="en">Review Article and Clinical Experience: Pleiotropic Properties of Statins (Potential Benefits of “PECA-GOMES” for the Elderly)</dc:title><dc:creator>Askandar Tjokroprawiro</dc:creator><dc:subject>statins</dc:subject><dc:subject>pleiotropy</dc:subject><dc:subject>coronary artery disease</dc:subject><dc:subject>elderly patients</dc:subject><dc:subject>LDL cholesterol lowering</dc:subject><dc:subject>atorvastatin</dc:subject><dc:subject>plaque stabilization</dc:subject><dc:subject>endothelial function</dc:subject><dc:subject>platelet function</dc:subject><dc:subject>cell-mediated immunity</dc:subject><dc:subject>anti-inflammatory activity</dc:subject><dc:subject>oxidized LDL</dc:subject><dc:subject>diabetes mellitus</dc:subject><dc:subject>cardiovascular risk factors</dc:subject><dc:subject>AVERT trial</dc:subject><dc:description xml:lang="en">Five major risk factors that modify LDL-Goals are (ATP-III 2001): family history of premature CHD, age (men ≥ 45 years; women ≥ 55 years), hypertension (BP ≥ 140/90 mmHg or on antihypertensive medication), low-HDL-Chol (&lt;40 mg/dl), and cigarette. Thus, it is obvious that the elderly can be included in one risk factor. In ATP-IIII, Diabetes Mellitus (DM) is regarded as a CHD risk equivalent. HDL-Chol ≥ 60 mg/dl counts as a “protective” factor; its presence removes one risk factor from the total count. Coronary Heart Disease (esp. for the elderly) remains a major therapeutic challenge in the world, and strategies aimed at cholesterol lowering from the primary target of treatment (LDL-Cholesterol &lt; 100 mg/dl) for patients with CHD, DM, and “Double Jeopardy” (DM plus CHD). Decreased LDL size is mainly associated with premature CHD, but it is likely that LDL particle size is not a major risk factor in the elderly. Three categories of risk that modify LDL Chol (mg/dl). Goals are:CHD and CHD risk equivalent (LDL &lt;100), Multiple (2+) risk factors (LDL &lt;130), Zero to one risk factor (LDL &lt;160). Statins (1 st Gen: Lovastatin, Simvastatin, Pravastatin; 2 nd Gen: Fluvastatin; 3 rd Gen: Atorvastatin, Resuvastatin) have the primary effect to reduce LDL-Chol. However, emerging evidence indicate that Statins (f.e Atorvastatin in MIRACL, AVERT, ASAP-Clinical Trials) reduce the incidence of recurrent ischemic events, and slow the progression of atherosclerotic CHD. These clinical effects may be due to the pleiotropic effects (non-lipid mechanism) of Statins. Many of the pleiotropic properties (minimally 20 items) of the Statins have been compiled by the author, and 9 of 20 such beneficial effects can be abbreviated as PECA-GOMES (stimulate Plaque Stabilization, improve Endothelial and Platelet Function, Cellular Immunity, Anti inflammatory Response – No Glucose Intolerance Effect, lower Oxidied LDL, decrease Macrophage number, inhibit Endothelin production, suppress SMC Proliferation and Migration). It is most likely that these non-lipid properties may play pivotal roles in plaque stabilization and in improving endothelial and platelet function which then contribute to an antithrombotic effect. Conclusion: Taken together, the results of several studies indicate that the effects of Statins may extend beyond cholesterol lowering. PECA-GOMES effects of Statins may be of great therapeutical benefits for the elderly. The results of Atorvastatin Trials support the pleiotropic effect of Statins in clinical practice.</dc:description><dc:publisher>Airlangga University</dc:publisher><dc:date>2003-04-01</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>http://journal.unair.ac.id/filerPDF/08%20AskandarE5.pdf</dc:identifier><dc:source>Folia Medica Indonesiana; Vol 39 No 2 (2003)</dc:source><dc:source>2355-8393</dc:source><dc:source>2599-056X</dc:source><dc:language>en</dc:language></oai_dc:dc>